Drugs Made In America Acquisition Corp
DMAA
39 hedge funds and large institutions have $237M invested in Drugs Made In America Acquisition Corp in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 6 closing their positions.
2% more capital invested
Capital invested by funds: $232M → $237M (+$5.27M)
0.68% more ownership
Funds ownership: 67.55% → 68.23% (+0.68%)
0% more funds holding
Funds holding: 39 → 39 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
+$13.8M |
| 2 |
MSU
Mizuho Securities USA
New York
|
+$5.92M |
| 3 |
MC
Meteora Capital
Boca Raton,
Florida
|
+$3.97M |
| 4 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$3.63M |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$2.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$13.1M |
| 2 |
MCS
Mercuria Capital Strategies
Houston,
Texas
|
-$7.51M |
| 3 |
JGC
J. Goldman & Co
New York
|
-$5.19M |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$3.59M |
| 5 |
GCL
Glazer Capital LLC
New York
|
-$1.44M |
DMAA Hedge Fund Activity: Q1 2026 in Review
39 of the 8,150 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition Corp (DMAA) for Q1 2026, worth a combined $237M — up 2.3% from $232M a quarter earlier.
Fund positioning in DMAA was balanced in Q1 2026: 6 funds opened new positions, 6 closed out, 7 added to existing stakes and 7 trimmed.
The largest buyer was Highbridge Capital Management, opening a new position worth an estimated $13.8M. The largest seller was Hudson Bay Capital Management, cutting an estimated $13.1M.
- 39 institutional investors held Drugs Made In America Acquisition Corp (DMAA) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $237M of Drugs Made In America Acquisition Corp stock for Q1 2026, up 2.3% quarter-over-quarter.
- 6 funds opened new Drugs Made In America Acquisition Corp positions in Q1 2026 and 6 closed out, a net change of 0 holders.
- The largest Drugs Made In America Acquisition Corp buyer in Q1 2026 was Highbridge Capital Management, an estimated $13.8M added.
- The largest Drugs Made In America Acquisition Corp seller in Q1 2026 was Hudson Bay Capital Management, an estimated $13.1M sold.
Based on aggregated 13F filings for Q1 2026.